Completed PHASE2 INTERVENTIONAL 1-arm NCT00837811

An Open Label Extension Study in Participants With Rheumatoid Arthritis

An Open Label Extension Study of Multiple Subcutaneous Doses of LY2127399 in Patients With Rheumatoid Arthritis.

Sponsor: Eli Lilly and Company

Interventions LY2127399

Updated 9 times since 2017 Last updated: Mar 24, 2018 Started: Feb 28, 2009 Primary completion: Jan 31, 2011 Completion: Jan 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Rheumatoid Arthritis, this trial is completed. The trial is conducted by Eli Lilly and Company and has accumulated 9 data snapshots since 2009. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

9 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Dec 2021 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Dec 2021 [monthly]

Completed PHASE2

▶ Show 4 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
May 2018 — Jun 2018 [monthly]

Completed PHASE2
Feb 2017 — May 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Feb 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Eli Lilly and Company

Data source: Eli Lilly and Company

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Baltimore, United States , Bialystok, Poland , Birmingham, United States , Brasov, Romania , Budapest, Hungary , Campinas, Brazil , Chełm Śląski, Poland , Chihuahua City, Mexico , Cuernavaca, Mexico , Curitiba, Brazil and 52 more locations